Given that highly specific SGLT2 inhibitors, SGLT2i, have been successfully introduced to treat T2DM and heart failure [3, 9], it has been natural to speculate about the use of SGLT2 inhibitors as a cancer therapy [10]. This evidence concerns the gene SLC5A2 and heart failure.